Topical Immunotherapy of Alopecia Areata

Steen, P.H.M. van der; Happle, Rudolf

doi:10.1016/s0733-8635(18)30255-9

Cited by 47 publications

(53 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While we therefore cannot comment as to whether our study findings apply to these subtypes, a response to SADBE has been previously noted across all alopecia subtypes in previous studies using protocols that both did and did not require the presence of an eczematous response after initial sensitization in order to pursue continued SADBE therapy. 6,7 In conclusion, SADBE sensitization regimens and reactions have great variability, and the absence of an initial eczematous reaction to sensitization may not predict a failed response with continued SADBE treatment. A larger group of patients may be candidates for SADBE therapy than certain treatment protocols imply, and an initial concentrated sensitization application may be unnecessary in some cases.…”

Section: Discussionmentioning

confidence: 96%

“…While some authors purport that the absence of an eczematous reaction does not imply that sensitization has failed and pursue treatment even in its absence, others specify the need for repeated sensitization attempts until such a reaction is noted and will declare treatment failure if such a reaction never occurs. [6][7][8] We aimed to compare these competing SADBE treatment paradigms by evaluating their efficacy at sensitization as measured by the ability to elicit hair regrowth.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Squaric acid sensitization is not required for response in the treatment of alopecia areata

Vedak

Kroshinsky

2015

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 96%

mentioning

confidence: 99%

Squaric acid sensitization is not required for response in the treatment of alopecia areata

Vedak

Kroshinsky

2015

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…If hair regrowth was not observed after the first 30 weeks, the patient was considered a nonresponder. 18 …”

Section: Treatment Methods With Dpcpmentioning

confidence: 99%

Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: A retrospective case series

Durdu

Özcan

Baba

et al. 2015

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…Response rates of topical immunotherapy with DPCP widely range from 4% to 85% in literature and this may be due to the difference in number of patients, type, duration and severity of AA as well as time of treatment and methods of evaluation [10,[24][25][26][27][28][29][30].…”

Section: Discussionmentioning

confidence: 99%

Effect of Fexofenadine as an Adjunct to DPCP in Non-Atopic Patients with Alopecia Areata: A Randomized Clinical Trial

Soltanahmadi¹

2012

J Clin Exp Dermatol

View full text Add to dashboard Cite

Introduction: In this study the effect of fexofenadine as an adjunct to diphenylcyclopropenone (DPCP) in nonatopic patients with Alopecia areata (AA) is investigated. Patients and methods:Prospectively 100 patients with AA having hair loss of more than 25% of the scalp are randomly divided into two groups in group A patients received topical DPCP plus oral fexofenafine, in group B patients received only topical DPCP. Results:Regrowth in group A was better than group B but this was not statistically significant. Eczematous reaction and pruritus was significantly lower in group A than in group B.Discussion: Fexofenadine seems to be of no benefit in patients without underlying contributing situation. Therefore, it can be added to conventional regimen in order to enhance the compliance of patients by reducing discomfort of DPCP treatment. Fexofenadine, an H1 receptor antagonist decreases the production of IFN-γ from T lymphocytes [13], as well as the expression of ICAM-1 on epithelial cells, supporting its efficacy for AA [14]. From these findings, antihistamines are expected to be effective for AA treatment. Indeed, the efficacy of antihistamines for AA has been reported [15][16][17][18][19]. Effect of Fexofenadine as anRecently, it has been reported that fexofenadine rapidly suppresses itch due to DPCP immunotherapy for AA, indicating that fexofenadine is an adequate concomitant drug [20]. Also it is found that fexofenadine is effective for AA of atopic background [19,21]. In this study which is a prospective randomized clinical trial we investigate the effect of fexofenadine as an adjunct to DPCP in non-atopic patients with AA. Patients and MethodsWe surveyed prospectively 100 patients with AA having hair loss of more than 25% of the scalp in Razi hospital from January 2009 to January 2011. We excluded patients with pregnancy, lactation, history of atopy, patients who had received systemic corticosteroid or any other medication within 3 months before starting point of evaluation or for AA; also we excluded patients with cardiovascular disease and blood dyscrasia; we randomly divided the patients into two groups (A and B), their age varied between 6 to 47 years. In group A there were 50 patients who received topical diphenylcyclopropenone (DPCP) plus oral fexofenafine, who took fexofenafine (120 mg/day for adults or 60 mg/day for children); in group B there were 50 patients who received only topical DPCP, in group A we lost 6 patients due to headache (1 patient), vitiligo (1 patient) and discontinue to follow up (4 patients), in group B we lost 4 patients, one patient due to severe eczematous reaction and 3 patients due to discontinue follow up (Figure 1).In group A there were 22 (44%) male and 28 (56%) female; in group B there were 26 (52%) male and 24 (48%) female the mean age was 25 ± 9.2 in group A and 24 ± 8.7 in group B. The severity of AA was evaluated using the Severity of Alopecia Tool (SALT) score proposed in the guidelines of the National Alopecia Areata Foundation [22,23]; S 0 : no hair loss; S...

show abstract

Topical Immunotherapy of Alopecia Areata

Cited by 47 publications

References 12 publications

Squaric acid sensitization is not required for response in the treatment of alopecia areata

Squaric acid sensitization is not required for response in the treatment of alopecia areata

Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: A retrospective case series

Effect of Fexofenadine as an Adjunct to DPCP in Non-Atopic Patients with Alopecia Areata: A Randomized Clinical Trial

Contact Info

Product

Resources

About